Clinical trialsCompany release

MapLight starts set-up of confirmatory Phase 3 ZEPHYR-2 in schizophrenia

🇺🇸 MapLight Therapeutics, Inc. (MPLT) · Mon 16 Nov 2026

The US biotech reported Q3 results on 16 November 2026, with cash of $463.4 million, and said Alzheimer's psychosis data from VISTA are now expected in 2028.

MapLight Therapeutics published its third-quarter results and a business update on 16 November 2026. The company said it has begun start-up activities for ZEPHYR-2, a confirmatory Phase 3 trial of ML-007C-MA in schizophrenia. It also plans to hold an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA). The title of the release puts cash at $463.4 million at the end of the third quarter.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): MapLight Therapeutics, Inc. ↗

Article written by VigiEye from the official source (MapLight Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →